Project Grant HT94252410732
Award Date
9/15/24
Completion Date
9/14/27
Dollars Obligated
$278K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA, USA
Similar Awards
This $380,785 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Pittsburgh. The award provides funding for a 3-year research project titled "MICROPARTICLE DELIVERY OF CHEMOKINE MUTEINS GUIDING CHEMOKINE RECEPTOR ENGINEERED TREG FOR TOLERANCE INDUCTION AFTER VASCULAR COMPOSITE ALLOGRAFT TRANSPLANT." The project aims to develop a microparticle-based delivery system to administer...
This $299,999 Project Grant award was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports research conducted by Wake Forest University Health Sciences (WFUHS) to develop microparticle delivery of chemokine muteins for guiding chemokine receptor engineered regulatory T cells (Tregs) to induce tolerance after vascular composite allograft transplants. The research project aims to advance therapeutic...
The University of Pittsburgh has been awarded a $540,800 Project Grant from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to conduct research on microparticle delivery of chemokine muteins guiding chemokine receptor engineered Treg for tolerance induction after vascular composite allograft transplant. The 3-year award, which runs from September 15, 2024 to September 14, 2027, will support innovative scientific studies aimed at developing novel...
This Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420) provides $1,592,860.00 to the Rector & Visitors of the University of Virginia (University of Virginia) to conduct ultrasensitive proteomics research for type 1 diabetes prediction and treatment efficacy assessment. The research aims to transform healthcare for military service members and the broader public by advancing disease prevention, diagnosis,...
This Project Grant award of $499,999.00, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program, supports research on nontoxic immunosuppression for vascularized composite allotransplantation (VCA) using vitamin D3 analogues. The award was made on September 1, 2024 to the University of Pittsburgh, a major public research university with extensive biomedical research capabilities. The research aims to advance disease...
The Project Grant award, titled "TARGETING MHCII UBIQUITINATION TO INDUCE IMMUNE REGULATION IN VASCULARIZED COMPOSITE TISSUE TRANSPLANTATION", is funded by the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program. The $992,302 award, effective from September 15, 2025 to September 14, 2028, is provided to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), a renowned nonprofit academic...
This federal Project Grant award, valued at $1,100,747.00 and provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research to engineer antibody-drug conjugates that can coordinate the innate and adaptive immune systems for curative responses. The primary awardee is the Regents of the University of Michigan, a prominent U.S. state government-owned educational institution with extensive expertise in federal research and...
This $305,917 federal Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports the development of an off-the-shelf reparative T regulatory cell (Treg) immunotherapy to limit tissue damage and initiate effective repair and resolution after lung injuries. The University of Pittsburgh, a major research institution, is the prime awardee on this 2-year grant with a performance period from December 1, 2023 to November 30,...
The federal Project Grant award of $999,806.00 from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research at The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to study innate lymphoid cells as new targets to reduce vascularized composite tissue transplant rejection. The award, which runs from September 30, 2024 to September 29, 2027, will enable MGH to conduct innovative biomedical research,...
This federal Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) provides $847,875.00 to the Rector & Visitors of the University of Virginia to conduct research on "Targeting Schwann Cell-Tumor Microenvironment Interactions in Neurofibroma Development". The research aims to advance understanding of the biological mechanisms underlying neurofibromas, with the goal of transforming healthcare for...